Eli Lilly and Company

This healthcare pharmaceutical giant and biotech stock is best known for its insulin products. But the company also develops a wide range of drugs including treatments for oncology, immunology, neurodegeneration, and cardiovascular disease. This century-old healthcare company has a loaded pipeline of medications waiting for FDA approval that could catapult your portfolio to new heights.

$861.69
(as of Feb 10, 12:40 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Eli Lilly and Company

Stock Price
$861.70
Ticker Symbol
LLY
Exchange
NYSE

Industry Information for Eli Lilly and Company

Sector
Healthcare
Industry
Drug Manufacturers - General

Company Description for Eli Lilly and Company

Country
USA
Full Time Employees
43,000

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Fundamentals for Eli Lilly and Company

Market Capitalization
$789,878,210,560
EBITDA
$16,566,500,352
Dividends per Share
$0
P/E Ratio
75.2
Forward P/E Ratio
38.46
Earnings per Share
$11.68
Earnings per Share Estimate Next Year
$29.28
Profit Margin
20.48%
Shares Outstanding
899,315,968
Percent Owned by Insiders
0.15%
Percent Owned by Institutions
83.25%
52-Week High
$970.92
52-Week Low
$711.40

Technical Indicators for Eli Lilly and Company

50-Day Moving Average
$790.84
200-Day Moving Average
$843.00
RSI
71.37
23.3

Analyst Ratings for Eli Lilly and Company

Strong Buy
15
Buy
6
Hold
6
Sell
1
Strong Sell
0

News About Eli Lilly and Company

Feb 9, 2025, 9:10 AM EST
Not all growth stocks worth buying these days focus on the artificial intelligence field. See more.
Feb 8, 2025, 1:50 PM EST
We recently compiled a list of the Billionaire Ken Fisher's Top 10 High Growth Stock Picks.In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks. See more.
Feb 8, 2025, 7:10 AM EST
We recently compiled a list of the 11 Best Stocks To Invest In For Grandchildren.In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks. See more.
Feb 7, 2025, 4:42 PM EST
Hims stock surged into a profit-taking zone Friday after facing backlash over its provocative Super Bowl ad that criticized the makers of approved weight-loss drugs. See more.